Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$95.51 +3.81%

+$3.89 today

Market cap
$6.24B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.78M

Average 0.95M

Returns on capital

Mirum Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-7.4%

avg -26.2%

ROIC

-3.5%

avg -30.6%

ROA

-2.8%

avg -27.5%

Analysis

ROA is currently the strongest return metric at -2.8% versus its period average of -27.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Christopher Peetz

Chief Executive Officer & DirectorUSD 1.83M4738.49K0.08%

Peter Radovich

Chief Operating Officer & PresidentUSD 1.16M4848.01K0.10%

Joanne J. Quan

Chief Medical OfficerUSD 1M62——

Eric H. Bjerkholt

Chief Financial OfficerUSD 1M66——

Lara Longpre

Chief Development OfficerUSD 678.2K56104.41K0.21%

Jean-Luc Girardet

Chief Technical Officer————

Andrew McKibben

Senior Vice President, Strategic Finance & Investor Relations————

Vinita Kumar

Senior Vice President of Quality————

Meredith Kiernan

Senior Director of Global Corporate Communications————

Erin Campany

Chief People Officer—58——

Douglas T. Sheehy

Chief Legal Officer & Secretary—59——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 4, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$9.00M

Sells

62

$45.34M

Net Transaction Value

−$36.34M

Net selling

Most Active

Peetz Christopher

20 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 11, 26

Brege Laura

Direct

Sell$1M
Nov 11, 26

Brege Laura

Direct

Sell$308.9K
Nov 4, 26

Peetz Christopher

Direct

Sell$1.8M
Sep 14, 26

BJERKHOLT ERIC

Direct

Sell$978.1K
Sep 2, 26

Howe Jolanda

Direct

Sell$65.8K
Sep 1, 26

Peetz Christopher

Direct

Sell$815.2K
Sep 1, 26

Peetz Christopher

Direct

Sell$2.1M
Aug 18, 26

Howe Jolanda

Direct

Sell$4M
Aug 11, 26

BJERKHOLT ERIC

Direct

Sell$599.5K
Aug 10, 26

Peetz Christopher

Direct

Sell$1.2M

1–10 of 63

Summary

Insiders reported 1 buys worth $9.00M and 62 sells worth $45.34M over the last 12 months. That adds up to net selling of $36.34M. Peetz Christopher was the most active insider with 20 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+89.1%
+31.4% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Recent growth has been strongest in Revenue at +89.1% over three years. Forward estimates point to Revenue at +31.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Mirum Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MIRM's management, answered from reported figures.

Who manages MIRM?

Mirum Pharmaceuticals, Inc. (MIRM) lists 11 active executives. The top listed executive is Jean-Luc Girardet, Chief Technical Officer.

Are MIRM insiders buying or selling?

Recent insider activity shows net selling of $3.35M.